FR2896881B1 - Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie - Google Patents

Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Info

Publication number
FR2896881B1
FR2896881B1 FR0600851A FR0600851A FR2896881B1 FR 2896881 B1 FR2896881 B1 FR 2896881B1 FR 0600851 A FR0600851 A FR 0600851A FR 0600851 A FR0600851 A FR 0600851A FR 2896881 B1 FR2896881 B1 FR 2896881B1
Authority
FR
France
Prior art keywords
prongf
therapy
determining
breast cancer
vitro diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0600851A
Other languages
English (en)
French (fr)
Other versions
FR2896881A1 (fr
Inventor
Kastylevsky Genevieve Choquet
Yohan Demont
Hubert Hondermarck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Universite Lille 1 Sciences et Technologies
Original Assignee
Biomerieux SA
Universite Lille 1 Sciences et Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0600851A priority Critical patent/FR2896881B1/fr
Application filed by Biomerieux SA, Universite Lille 1 Sciences et Technologies filed Critical Biomerieux SA
Priority to JP2008552858A priority patent/JP5091876B2/ja
Priority to PCT/FR2007/050708 priority patent/WO2007088305A1/fr
Priority to CN2007800040238A priority patent/CN101395478B/zh
Priority to CN2013103889291A priority patent/CN103446585A/zh
Priority to US12/087,606 priority patent/US8008009B2/en
Priority to EP07731536.4A priority patent/EP1982192B1/fr
Priority to ES07731536.4T priority patent/ES2471126T3/es
Publication of FR2896881A1 publication Critical patent/FR2896881A1/fr
Application granted granted Critical
Publication of FR2896881B1 publication Critical patent/FR2896881B1/fr
Priority to US13/137,101 priority patent/US20110293636A1/en
Priority to JP2012124525A priority patent/JP5792121B2/ja
Priority to US13/533,908 priority patent/US9061045B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0600851A 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie Expired - Fee Related FR2896881B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0600851A FR2896881B1 (fr) 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
ES07731536.4T ES2471126T3 (es) 2006-01-31 2007-01-30 Procedimiento de ensayo del ProNGF para el diagnóstico in vitro del cáncer, en particular del cáncer de mama, de tiroides, de la pr�stata o de pulmón, y utilización del proNGF en terapia
CN2007800040238A CN101395478B (zh) 2006-01-31 2007-01-30 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途
CN2013103889291A CN103446585A (zh) 2006-01-31 2007-01-30 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途
US12/087,606 US8008009B2 (en) 2006-01-31 2007-01-30 Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF
EP07731536.4A EP1982192B1 (fr) 2006-01-31 2007-01-30 PROCEDE DE DOSAGE DU ProNGF POUR LE DIAGNOSTIC IN VITRO DU CANCER EN PARTICULIER DU CANCER DU SEIN, DE LA THYROIDE, de la prostate, OU DU POUMON ET UTILISATION DU PRONGF EN THERAPIE
JP2008552858A JP5091876B2 (ja) 2006-01-31 2007-01-30 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
PCT/FR2007/050708 WO2007088305A1 (fr) 2006-01-31 2007-01-30 Procede de dosage du prongf pour le diagnostic in vitro du cancer en particulier du cancer du sein, de la thyroide ou du poumon et utilisation du prongf en therapie
US13/137,101 US20110293636A1 (en) 2006-01-31 2011-07-20 Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf
JP2012124525A JP5792121B2 (ja) 2006-01-31 2012-05-31 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
US13/533,908 US9061045B2 (en) 2006-01-31 2012-06-26 Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600851A FR2896881B1 (fr) 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Publications (2)

Publication Number Publication Date
FR2896881A1 FR2896881A1 (fr) 2007-08-03
FR2896881B1 true FR2896881B1 (fr) 2008-04-18

Family

ID=36741378

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0600851A Expired - Fee Related FR2896881B1 (fr) 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Country Status (7)

Country Link
US (3) US8008009B2 (https=)
EP (1) EP1982192B1 (https=)
JP (2) JP5091876B2 (https=)
CN (2) CN103446585A (https=)
ES (1) ES2471126T3 (https=)
FR (1) FR2896881B1 (https=)
WO (1) WO2007088305A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
FR2944019B1 (fr) * 2009-04-03 2011-04-22 Biomerieux Sa Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal.
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
CN101782585A (zh) * 2010-02-10 2010-07-21 广州医学院 肺癌组织蛋白印迹膜片及其制备方法
US20130115222A1 (en) * 2010-06-15 2013-05-09 Cornell University Methods of limiting microvascular damage following acute myocardial ischemia
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US20140295426A1 (en) * 2011-07-28 2014-10-02 Veridex Llc Methods for Diagnosing Cancer by Characterization of Tumor Cells Associated with Pleural or Serous Fluids
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
CN103122390B (zh) * 2013-03-07 2015-04-08 上海市疾病预防控制中心 Frat1基因作为检测甲状腺癌的血清标志物及其应用
EP3626308A1 (en) 2013-03-14 2020-03-25 Veracyte, Inc. Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN103866039B (zh) * 2014-04-04 2015-05-27 厦门大学 人类甲状腺癌组织基因特异位点甲基化水平检测引物及其应用
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP2977759B1 (en) * 2014-07-25 2017-07-12 Serum Institute of India Private Limited Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
JP2020508643A (ja) * 2017-01-24 2020-03-26 ジェネティック テクノロジーズ リミテッド 乳癌発症リスクの改良された評価法
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
CA3066507A1 (fr) * 2017-06-08 2018-12-13 Carcidiag Biotechnologies Methode d'isolement et de detection de cellules souches cancereuses
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
AU2003242815A1 (en) 2002-03-13 2003-09-22 Biomerieux Method for the characterisation of circulating tumour cells stemming from solid cancers
FR2846426B1 (fr) 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
AU2003287930A1 (en) * 2002-12-20 2004-07-14 Neuronicon Aps Modulation of activity of neurotrophins
WO2005076695A2 (en) * 2004-02-11 2005-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Also Published As

Publication number Publication date
JP2012211148A (ja) 2012-11-01
US20110293636A1 (en) 2011-12-01
WO2007088305A1 (fr) 2007-08-09
CN101395478A (zh) 2009-03-25
JP5792121B2 (ja) 2015-10-07
CN103446585A (zh) 2013-12-18
JP2009525478A (ja) 2009-07-09
FR2896881A1 (fr) 2007-08-03
EP1982192A1 (fr) 2008-10-22
US9061045B2 (en) 2015-06-23
US20130171173A1 (en) 2013-07-04
ES2471126T3 (es) 2014-06-25
US20090068200A1 (en) 2009-03-12
US8008009B2 (en) 2011-08-30
EP1982192B1 (fr) 2014-03-26
CN101395478B (zh) 2013-08-28
JP5091876B2 (ja) 2012-12-05

Similar Documents

Publication Publication Date Title
FR2896881B1 (fr) Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
FR2919065B1 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919064B1 (fr) Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
EP2004230A4 (en) N-CADHERINE AND LY6 E: OBJECTIVES FOR CANCER DIAGNOSIS AND THERAPY
EP2029020A4 (en) USE OF STROMA COLLAGEN IN THE DIAGNOSIS AND CHARACTERIZATION OF BREAST CANCER
FR2906808B1 (fr) Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
EP2184997A4 (en) DIAGNOSIS AND TREATMENT METHODS FOR THE CHARACTERIZATION OF BACTERIAL MICROORGANISMS IN SKIN DISEASES
EP1692318A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
EP1662965A4 (en) FORMULATIONS AND METHOD FOR THE TREATMENT OF BREAST CANCER WITH MORINDA CITRIFOLIA AND METHYLSULFONYLMETHANE
EP1872124A4 (en) DIAGNOSIS MARKET FOR BREAST CANCER TREATMENT AND PROGRESSION AND METHOD OF USE THEREOF
GB0909829D0 (en) Thermomastographic apparatus for differentiation for detecting breast pathology in women and use of the thermomastographic apparatus for differentiation
EP2211913A4 (en) SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
EP2056808A4 (en) Small molecule potentiator of hormonal therapy for breast cancer
EP2155249A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
EP1869222A4 (en) METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2059210A4 (en) THERAPEUTIC DEVICES FOR TREATING VARIOUS WOMEN'S DRESS
EP2315602A4 (en) METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS
EP1968648A4 (en) DIAGNOSIS SYSTEM FOR THE DETECTION AND DIAGNOSIS OF SKIN CANCER
EP2216344A4 (en) DIAGNOSIS AND TREATMENT OF CANCER WITH AN ANTI-GPR49 ANTIBODY
EP2744917A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER
EP2062597A4 (en) PREVENTIVE OR CLEANING AGENT FOR ER-NEGATIVE AND HER2-NEGATIVE MAMMARY CARCINOMA AND INVESTIGATION METHOD THEREFOR
EP2148675A4 (en) ANTI-CANCER FOR THE DIAGNOSIS AND TREATMENT OF CANCER
FR2944019B1 (fr) Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal.
EP2094866A4 (en) DIAGNOSIS AND TREATMENT OF BREAST CANCER

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20160930